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Lithium, the long-standing hallmark treatment for bipolar disorder, has recently been
identified as a potential neuroprotective agent in neurodegeneration. Here we focus on
introducing numerous in vitro and in vivo studies that have shown lithium treatment to be
efficacious in reducing oxidative stress and inflammation, increasing autophagy, inhibiting
apoptosis, and decreasing the accumulation of α-synulcein, with an emphasis on
Parkinson’s disease. A number of biological pathways have been shown to be involved in
causing these neuroprotective effects. The inhibition of GSK-3β has been the mechanism
most studied; however, other modes of action include the regulation of apoptotic proteins
and glutamate excitotoxicity as well as down-regulation of calpain. This review provides
a framework of the neuroprotective effects of lithium in neurodegenerative diseases
and the putative mechanisms by which lithium provides the protection. Lithium-only
treatment may not be a suitable therapeutic option for neurodegenerative diseases due
to inconsistent efficacy and potential side-effects, however, the use of low dose lithium in
combination with other potential or existing therapeutic compounds may be a promising
approach to reduce symptoms and disease progression in neurodegenerative diseases.
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INTRODUCTION
Lithium, introduced in 1949, is the most commonly used drug for the treatment of bipolar
disorder, a chronic mental illness characterized by manic and depressive cycles. The efficacy of
lithium in treating acute mania is long-established, and it is the standard against which other
medications for bipolar disorder are measured (Young and Hammond, 2007). Meta-analysis
of 14 randomized control samples showed that lithium, when used prophylactically, primarily
reduced manic relapses, although its efficacy in reducing depressive relapses was significantly lower
Abbreviations: 3-NPA, 3-nitropropionic acid; 6-OHDA, 6-hydroxydopamine; AD, Alzheimer’s disease; AIMs, abnormal
involuntary movements; ALS, amyotrophic lateral sclerosis; AP-1, activator protein-1; APP, amyloid precursor protein; Akt,
protein kinase B; BAD, Bcl2-associated agonist of cell death; BAK, Bcl2-antagonist/killer; Bax, Bcl-2–associated X protein;
Bcl, B-cell lymphoma; BDNF, brain derived neurotrophic factor; CAT, catalase; Cdk, cyclin dependent kinase; DOPAC,
dihydroxyphenyl acetic acid; ERK, extracellular signal-regulated kinase; FOXO, forkhead box class O; GSH, glutathione
peroxidase; GSK, glycogen synthase kinase; HD, Huntington’s disease; IMPase, inositol monophosphatase; IP3, inositol
1,4,5-trisphosphate; JNK, Jun N-terminal kinase; MCI, mild cognitive impairment; MDM, murine double minute; MEF,
myocyte enhancement factor; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NPCs, neural progenitor cells; NT-3,
neurotrophin 3; NT-4, neurotrophin 4; PD, Parkinson’s disease; SNpc, substantia nigra pars compacta; SOD, superoxide
dismutase; Tcf, T-cell factor; TH, tyrosine hydroxylase; TrkA, receptor tyrosine kinase A; TrkB, receptor tyrosine kinase B;
TrkC, receptor tyrosine kinase C; VPA, valproic acid.
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(Smith et al., 2007). Additional meta-analyses showed that
lithium treatment reduced the number of suicides and suicide
attempts in individuals with mood disorders (Cipriani et al.,
2005; Baldessarini et al., 2006).
A growing body of evidence suggests that the benefits of
lithium extend beyond mood stabilization. Lithium treatment
has been shown to provide neuroprotection against neurological
insults including excitotoxicity, ischemic damage, and traumatic
brain injury (Basselin et al., 2006; Zhu et al., 2010). In addition,
lithium has been shown to contribute to remyelination and
axonal regeneration (Makoukji et al., 2012). In particular, lithium
treatment has been associated with neuroprotection against
neurodegenerative conditions such as Parkinson’s, Alzheimer’s,
and Huntington’s diseases as well as Amyotrophic Lateral
Sclerosis (ALS). This review focuses on the effects of lithium on
Parkinson’s disease and some of the presumed mechanisms by
which lithium provides its protective properties.
While studies suggest lithium can be an efficacious treatment
for mood disorders and neurodegenerative conditions, there are
several reports about lithium-induced neurotoxicity that, at its
worst, is irreversible. High lithium doses are generally required
for inducing neurotoxicity, however, it can occur at therapeutic
dosages as well (Donaldson and Cuningham, 1983). The signs
exhibited by the effected patients were mostly extrapyramidal
in nature (Johnels et al., 1976; Kane et al., 1978; Ghadirian and
Lehmann, 1980). There have also been reports of patients with
cerebellar signs and Creutzfeldt-Jakob disease-like syndrome
induced by lithium treatment (Smith and Kocen, 1988; Finelli,
1992). Research has shown, however, a correlation between lower
doses of lithium and lower side-effects (Abou-Saleh and Coppen,
1989).
Parkinson’s Disease (PD) is a basal ganglia disease, which
associates with clinical motor symptoms such as bradykinesia,
akinesia, resting tremor, muscular rigidity and postural
instability, and non-motor symptoms of sleep disturbance,
constipation, dysarthria, dysphonia, dysphagia, sialorrhoea,
urinary incontinence and, “at the last, constant sleepiness
with slight delirium” (Parkinson, 2002). Pathologically, PD
is characterized by intracytoplasmic Lewy body inclusions
and degeneration of dopaminergic neurons primarily in
the substantia nigra pars compacta (SNc). Like other
neurodegenerative diseases, the etiology of PD is largely
unknown. Less than 10% of cases are probably caused by genetic
mutations, most notably, in the gene encoding the presynaptic
alpha-synuclein protein (Polymeropoulos et al., 1997). Some
studies have demonstrated that prolonged occupational exposure
to certain chemicals, particularly pesticides and heavy metals,
such as Fe, Mn, Zn and Cu, is associated with an elevated risk of
PD (Betarbet et al., 2000; Fukushima et al., 2013; Stelmashook
et al., 2014).
LITHIUM EFFECTS IN PARKINSON’S
DISEASE
Diverse lithium studies in Parkinson’s disease have been executed
and included both in vitro and in vivo experiments. MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and 6-OHDA
(6-hydroxydopamine) have been used to generate PD animal
models and have been shown to activate the pro-apoptotic
cysteine protease, caspase-3. In human neuroblastoma SH-
SY5Y cells treated with MPP+ and in cultured rat cerebellar
granule neurons treated with 6-OHDA, lithium inhibited the
caspase-3 activation and prevented cell death (King et al.,
2001; Chen et al., 2004). Endoplasmic reticulum (ER) stress,
in combination with abnormal protein degradation has been
implicated in the pathophysiology of PD as well as other
neurodegenerative diseases (Lindholm et al., 2006). Lithium,
via GSK inhibition, has been shown to protect cells from
ER stress-induced lipid accumulation (Kim et al., 2005). In
addition, chronic low-dose lithium exposure on SH-SY5Y cells
demonstrated its neuroprotective effects, possibly mediated
by regulating stress gene expression, stimulating glycolysis,
accumulating extracellular pyruvate, and inducing resistance
to oxidative stress due to nuclear factor erythroid 2-related
factor 2 (NRF)-2 activation and miR-34a inhibition (Nciri
et al., 2013; Alural et al., 2015). Similarly, lithium was found
to be protective against oxidative stress in rat dopaminergic
N27 cells which over-express A53T alpha-synuclein. In the
brains of alpha-synuclein A53T over-expressing transgenic
mice, lithiumprevents/degrades paraquat/maneb-induced alpha-
synuclein protein aggregation (Kim et al., 2011). Chronic lithium
treatment in vivo and in vitro in the absence of either neurotoxin
showed significant increases in tyrosine hydroxylase in the
frontal cortex, hippocampus, and striatum of rats and mice as
well as in human neuroblastoma SH-SY5Y and rat dopaminergic
N27 cells (Chen et al., 1998; Lieu et al., 2014; Lazzara et al.,
2015).
The combination of low-dose lithium and L-Dopa/Carbidopa
(Sinemet R©) in MPTP-lesioned mice has been shown to
reduce MPTP-induced abnormal involuntary movements
(AIMs) (Lazzara et al., 2015), while in another study using the
MPTP-induced PD mouse model, combined administration
of lithium and valproate improved motor function and
increased the number of dopaminergic neurons in the
substantia nigra, compared to controls. There was also a
decrease in the concentration of the dopamine metabolite,
dihydroxyphenyl acetic acid (DOPAC), in both the MPTP-
treated and control groups; however, DOPAC loss was less severe
in mice receiving the combined lithium-valproate treatment (Li
et al., 2013).
Lithium has been considered as a potential apoptotic
inhibitor. Studies in PD animal models have demonstrated
that lithium can prevent MPTP-induced dopamine depletion
and stimulate the up-regulation of B-cell lymphoma 2 (Bcl-2)
and the down-regulation of Bcl-2–associated X protein (Bax)
in the striatum (Youdim and Arraf, 2004). Over-expression
of Bax hastens apoptotic cell death, which can be reduced
by lithium’s anti-apoptotic effect (Oltval et al., 1993). Bcl-
2, on the other hand, is a proto-oncogene that is one of
the key regulators of apoptosis. Over-expression of Bcl-
2 provides protection against dopaminergic neurotoxins,
by which lithium may reduce apoptosis (Offen et al.,
1998).
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PUTATIVE MODES OF ACTION OF LITHIUM
Numerous in vitro and in vivo studies over the last two decades
have demonstrated that lithium provides neuroprotection, and
as such, has the potential to become a therapeutic agent
in the treatment of neurodegenerative diseases. Mechanisms
of action of lithium include activating neurotrophic and
neuroprotective cellular cascades, reducing oxidative stress, and
decreasing apoptosis and inflammation. It has also been shown to
enhance neurotrophic factors, reduce excitotoxicity, and provide
mitochondrial stability (see Figure 1).
Inhibition of GSK-3
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase
that is involved in a number of intracellular signaling pathways.
It exists in two isoforms, α and β. Dysfunction of the protein
plays a role in the pathogenesis of both sporadic and familial
forms of Alzheimer’s disease. Up-regulation of GSK-3 activity
leads to phosphorylation of the amyloid precursor protein (APP)
and the protein tau, both of which are associated with the
pathological processes that lead to the hallmarks of Alzheimer’s
disease (AD), amyloid-β plaques and neurofibrillary tangles
(Hanger and Noble, 2011; Avila et al., 2012). Interestingly, in
the MPTP mouse model, α-synuclein contributes to tau hyper-
phosphorylation, an effect that is mediated by the activation of
GSK-3β. This robust activation of GSK-3β was also observed
in SH-SY5Y cells co-transfected with hDAT, mesencephalic
neurons, striata of transgenic mice overexpressing α-synuclein,
and in the postmortem striata of PD patients (Duka et al., 2009).
A number of researchers have demonstrated that lithium
at concentrations of 1–2mM inhibits GSK-3 (Bauer et al.,
2003; Rowe and Chuang, 2004; Gould and Manji, 2005; Rowe
et al., 2007). Lithium has been shown to reduce GSK-3 activity
in two ways—both directly and indirectly—by increasing the
inhibitory phosphorylation of GSK-3. The direct path by which
GSK-3 is inhibited by lithium is via direct competition for a
magnesium-binding site with GSK-3β (Jope, 1999). The indirect
regulation of GSK-3 activity by lithium is through the activation
of protein kinase B (also known as Akt). It is thought that the
activation of Akt may provide additional neuroprotective effects
downstream via modulation of forkhead box class O (FOXO),
Bcl-2-associated death protein (Bad) (a pro-apoptotic protein of
the Bcl-2 family), and murine double minute (MDM; Beaulieu
et al., 2004, 2007; Avila and Hernández, 2007; Alural et al.,
FIGURE 1 | Potential targets of cytoprotective effects by lithium. Target pathways of lithium in neurodegenerative diseases described in the article are marked
by section number (right top). Akt, protein kinase B; Bcl, B-cell lymphoma; BDNF, brain derived neurotrophic factor; Cdk, cyclin dependent kinase; ERK, extracellular
signal-regulated kinase; GSK, glycogen synthase kinase; IMPase, inositol monophosphatase; IP3, inositol 1,4,5-trisphosphate; MEF, myocyte enhancement factor;
Tcf, T-cell factor; TH, tyrosine hydroxylase; TrkB, receptor tyrosine kinase B.
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2015). Further, this inhibition of GSK-3 by lithium correlates
with reduced tauopathy and degeneration in vivo (Hong et al.,
1997; Noble et al., 2005). However, the lithium-induced GSK-
3β regulation may be an acute down-regulation since chronic
lithium exposure does not appear to have an impact on the level
of GSK-3β expression nor its activity (Kim et al., 2011; Nciri et al.,
2015).
Inhibition of Oxidative Stress
Oxidative stress is believed to be one of the underlying causes
of cellular dysfunction and death in PD. In PD patients, the
cells in the SNpc exhibit increased levels of oxidative stress-
induced damage in lipids, proteins, and DNA and decreased
levels of glutathione (GSH) (Bosco et al., 2006; Nakabeppu et al.,
2007; Zeevalk et al., 2008). The primary markers of oxidative
stress include thiobarbituric acid reactive substances and
regulation of several enzymes—superoxide dismutase (SOD),
catalase (CAT) and glutathione peroxidase (Wang et al., 2003).
When stress conditions are increased, SOD levels increase as
well, leading to an elevated SOD/CAT ratio. An increase in
oxidative stress is often linked to an increase in the cellular
hydrogen peroxide concentration inducing lipid peroxidation in
membranes, proteins and genes (Gsell et al., 1995).
In several in vitro studies, lithium administration was found to
inhibit hydrogen peroxide-induced cell death as well as obstruct
lipid peroxidation and protein oxidation in cortical cells (Shao
et al., 2005; de Vasconcellos et al., 2006; Cui et al., 2007; Frey et al.,
2007; Machado-Vieira et al., 2007; Kim et al., 2011). In addition,
the ability of lithium to act as an anti-oxidant was ascribed to
an increase in GSH levels in neurons, rat dopaminergic N27,
and human SH-SY5Y neuroblastoma cells (de Vasconcellos et al.,
2006; Kim et al., 2011).
Activation of Brain Derived Neurotrophic
Factor/Receptor Tyrosine Kinase B
Brain derived neurotrophic factor (BDNF) helps to regulate
neuronal and synaptic development and support the survival
and plasticity of existing neurons (McAllister et al., 1999).
The receptor tyrosine kinase B (TrkB) is activated by and
facilitates the effects of the neurotrophins: BDNF, neurotrophin-
3 (NT-3), and neurotrophin-4 (NT-4). These effects include
neuronal differentiation and survival (Yoshii and Constantine-
Paton, 2010).
Chronic lithium treatment was shown to significantly increase
BDNF expression in the hippocampus as well as temporal and
frontal cortices of rat brain; however, it was not accompanied
by an increase in TrkB levels (Fukumoto et al., 2001). In a
study which used primary cultures of rat cortical neurons,
results with wild type and BDNF heterozygous and homozygous
knock-outs showed that lithium application activates the
BDNF/TrkB signaling pathway and protects neurons from
glutamate excitotoxicity (Figure 1; Hashimoto et al., 2002). In
two separate in vitro studies utilizing neural progenitor cells
(NPCs), it has been suggested that lithium up-regulates BDNF
production as evidenced by maximal cellular proliferation and
neuronal differentiation (Su et al., 2007, 2009). It has been
demonstrated that lithium increases mRNA of NGF, but not
TrkA in rats, and inhibits TrkA-mediated signaling in PC12
cell cultures. In addition, NT-3 mRNA was decreased, but
the mRNA of its receptor TrkC was increased by lithium
(Burstein et al., 1985; Mudò et al., 1996). Although the cell
proliferation effect by lithium in brain can be controversial,
lithium-induced hippocampal neurogenesis in adult rodents has
been reported by several groups (Fiorentini et al., 2010; O’Leary
et al., 2012).
Inhibition of the Calpain—Cdk5 Pathway
In the MPTP-induced PD mouse model, Smith et al.
demonstrated a mechanism for dopaminergic neuronal loss
which involves the downstream pathway of calpain-1 (2006).
This mechanism includes modulation of the transcription
factor myocyte enhancer factor 2 (MEF2) via cyclin dependent
kinase 5 (Cdk5). A co-activator of Cdk5, p35, is converted
to p25, a pathogenic form, by calpain-mediated cleavage of
p35. Cdk5, bound to p25, becomes pro-apoptotic and leads
to phosphorylation of MEF2 at Ser444, an inactivating site.
The inactivation of MEF2 plays a critical role in dopaminergic
cell loss (Smith et al., 2006). There has been no evidence that
lithium inhibits calpain activity directly (Sasaki et al., 2006);
however, it has been shown that lithium treatment robustly
inhibits NMDA-receptor mediated calcium influx (Nonaka
et al., 1998). As calpain activation is tied to calcium influx, it
may be reasonable to speculate that lithium down-regulates
calpain via this mechanism. We recently reported that lithium
suppresses MPTP-induced calpain-1 expression and activity,
which is very likely up-stream of MEF2 and tyrosine hydroxylase
(TH) in the mouse brain. The efficacy of lithium for PD is,
in part, derived from increased dopamine synthesis through
TH-upregulation (Lazzara et al., 2015). The calpain-mediated
Cdk5 pathway can be a known target for AD pathology as
well. For example, the loss of regulation of Cdk5 has also been
implicated in the formation of the pathological characteristics
and the neurodegeneration associated with AD. An in vivo study
using mice has revealed that the neurotoxic Cdk5 activator,
p25, resulted in increased inflammation, deposition of amyloid
and phosphorylated tau, and neuronal death. (Cruz and Tsai,
2004). The use of Cdk5 inhibitory peptide has been shown to
reduce the effects of increased activation of Cdk5/p25 in mice,
exhibiting decreased neuroinflammation, brain atrophy and
cognitive decline (Sundaram et al., 2013). Lithium treatment
in cultured cerebellar granule neurons prevents the increase of
Cdk5/p35 fragmentation to Cdk5/p25 induced by colchicine
(Jordà et al., 2005). In addition, treatment of cultured primary
hippocampal neurons and rat striatum with lithium down-
regulated calpain activity, Cdk5 activation, and cellular death
induced by 3-nitropropionic acid (3-NPA) (Crespo-Biel et al.,
2009).
It has been established that GSK3β is a key mediator of
tau hyper-phosphorylation, and that lithium treatment inhibits
GSK3β and consequently, tau hyperphosphorylation. Plattner
et al. has demonstrated a connection between GSK-3β and
Cdk5, showing that Cdk5 acts as a modulator of tau hyper-
phosphorylation via the inhibitory regulation of GSK-3 (Plattner
et al., 2006).
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Regulation of Apoptotic Proteins and
Glutamate Excitotoxicity
Lithium has also been shown to influence levels of pro-
apoptotic proteins. Bax, also known as Bcl-2–associated X
protein, is a regulator that promotes apoptosis by binding to and
antagonizing the Bcl-2 protein. The tumor suppressor protein,
p53, targets both Bcl-2 and Bax and promotes growth arrest and
cell death in response to cell damage (Basu and Haldar, 1998). In
addition to being a major anti-apoptotic protein, Bcl-2 has been
shown to induce regeneration of axons after injury (Huang et al.,
2003).
A number of in vitro and in vivo experiments have
demonstrated the neuroprotective effects of lithium attributed to
increased Bcl-2 levels. Lithium treatment of cultured cerebellar
granule cells stimulated an increase of mRNA and protein levels
of Bcl-2; the Bcl-2/Bax protein level ratio increased by 5-fold
after treatment for 5–7 days (Chen and Chuang, 1999). Lithium-
induced increases in Bcl-2 expression were shown to cause
neurogenesis in the hippocampus and entorhinal cortex in adult
rodents as evidenced by an increase of axon diameters and
improved neurite growth in the CA3 area of the hippocampus
and an increase of myelination in the entorhinal cortex (Chen
et al., 2000). In theMPTP-inducedmouse PDmodel, a diet which
included a high dose of lithium almost completely prevented the
depletion of striatal dopamine and tyrosine hydroxylase, and the
expected increase in dopamine turnover was prevented. Lithium
was credited with providing neuroprotection by stimulating
anti-apoptotic activity—increasing Bcl-2 level and reducing Bax
(Youdim and Arraf, 2004). Phosphorylation of Bcl-2 at serine
70 is required for its complete anti-apoptotic function (Ruvolo
et al., 2001), and Chen et al. have shown that lithium blocks
induced apoptosis in mouse T hybridoma cells treated with
ceramide and etoposide (2006). In this model, lithium inhibited
Bcl-2 dephosphorylation and caspase-2 activation via reduction
of protein phosphatase-2A activity (Chen et al., 2006). Changes
in the expression of Bcl-2 and other pro-apoptotic genes have also
been detected in human subjects taking lithium. The peripheral
blood of patients with bipolar disorder was studied to observe
changes in the gene expression profiles over time following
treatment with lithium. This analysis identified the apoptotic
pathway as the most affected by lithium, as after 1 month, those
patients who responded positively to lithium treatment showed
up-regulation of Bcl-2, while several pro-apoptotic genes, e.g.,:
Bcl-2-antagonist/killer 1 (BAK1) and Bcl-2-associated agonist of
cell death (BAD), were down-regulated (Lowthert et al., 2012).
Glutamate-induced excitotoxicity has been implicated in
various neurodegenerative diseases including Huntington’s
disease, AD, and ALS, as well as in stroke, trauma and spinal cord
injury (Friedlander, 2003; Lau and Tymianski, 2010). A number
of studies have also associated glutamate-mediated excitotoxicity
in the pathogenesis of PD. PARK2 is the E3 ubiquitin ligase
parkin-encoding gene; its mutations cause PD. Mutations to the
PARK2 gene can lead to an abnormally small parkin protein
that is non-functional and is rapidly degraded. Parkin has also
been shown to be involved in the function and stability of
glutamatergic synapses. Further, the parkin mutations linked
to PD trigger a proliferation of glutamatergic synapses with
concomitant susceptibility to excitotoxicity (Helton et al., 2008).
Glutamate excitotoxicity has been shown to be associated
with the up-regulation of Bax and p53, both of which are pro-
apoptotic proteins, and the down-regulation of Bcl-2 (Chen
and Chuang, 1999). The apoptosis attributed to glutamate was
shown to be preceded by an increase in activator protein-1
(AP-1) caused by activation of c-Jun N-terminal kinase (JNK)
and p38 mitogen-activated protein kinase (MAP kinase) and
phosphorylation of c-Jun (Ser63) and p53 (Ser15) (Chen et al.,
2003). In a study using cultured rat cerebellar granule cells,
treatment with lithium prevented these signaling events and
ameliorated the increase in apoptosis (Chi-Tso and Chuang,
2011).
Other Proposed Pathways
There are a number of additional mechanisms by which lithium
has been shown to act intracellularly. These include modification
of cyclic adenosine monophosphate (cAMP)-mediated signal
transduction (Jope, 1999; Gould et al., 2002; Einat et al.,
2003); reduction in the arachidonic acid (AA) cascade (Chang
et al., 1996, 2001; Chang and Jones, 1998; Rintala et al., 1999;
Rapoport and Bosetti, 2002); negative regulation of the Smad3/4-
transcription factor and protein levels of plasminogen activator
inhibitor-1 (PAI-1); and induction of neurogenesis (Chen et al.,
2000; Hashimoto et al., 2003). In addition, lithium has been
shown to induce the survival pathway, MEK/ERK (Liang et al.,
2008); increase levels of transcription factor β-catenin (Stambolic
et al., 1996; Gould et al., 2004); and regulate autophagy via
inositol inhibition and reduction of inositol 1, 4, 5-trisphosphate
(IP3) levels (Sarkar et al., 2005; Sarkar and Rubinsztein, 2006,
2008; Fornai et al., 2008a; Klionsky et al., 2012).
LITHIUM EFFECTS IN OTHER
NEURODEGENERATIVE DISEASES
Alzheimer’s Disease
Abnormal levels of GSK-3 are associated with pathogenesis and
neuronal death in individuals with AD (Bhat et al., 2004), and
lithium has been shown to inhibit the GSK-3-related toxicity
(Stambolic et al., 1996). In 1997, researchers demonstrated
that lithium reduces phosphorylated tau in vitro and in vivo
by inhibition of GSK-3 (Hong et al., 1997; Muñoz-Montaño
et al., 1997). Lithium also prevented tau hyper-phosphorylation,
thereby blocking its neurotoxicity and associated cell death
(Alvarez et al., 1999). Further, lithium treatment resulted in
a significant reduction of GSK-3 activity with concomitant
decreases in the AD-associated tau phosphorylation, insoluble,
aggregated tau accumulation, and axonal degeneration (Noble
et al., 2005).
Various studies with AD animal models have shown that
lithium can also provide beneficial effects. For example, aged
double transgenic mice (AβPPSwe/PS1A246E) that display
amyloid deposits were treated with lithium and showed
attenuated γ-cleavage of amyloid precursor protein (APP)
followed by reduction in amyloid-β plaque formation. These
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animals also showed improvement in spatial learning and
memory abilities in addition to reduced autophagy activation
(Zhang et al., 2010).
The promising studies showing GSK-3 inhibition by lithium
have prompted many researchers to regard lithium as a potential
therapeutic agent for the prevention and treatment of Alzheimer’s
disease. However, most clinical trials have provided ambiguous
or inconsistent results. A case-control study using data from
the General Practice Research Database in the UK showed
that patients who received lithium treatment had a higher risk
of diagnosis of dementia, which was believed to correlate to
higher doses of the drug (Dunn et al., 2005). In a placebo-
controlled, randomized, single-blind, multicenter study, lithium
was given to 71 AD patients over a period of 10 weeks.
CSF and plasma biomarkers (total tau, phosphorylated tau,
Aβ42 and GSK-3) were monitored during that time period,
and there was no significant difference in the biomarkers or
in cognitive performance as compared to patients receiving a
placebo (Hampel et al., 2009). However, in a 2007 study that
compared elderly, bipolar patients (who are at a higher risk for
dementia) who had received chronic lithium treatment, with
bipolar patients who had not received lithium, it was shown that
the lithium-treated patients had lower prevalence of dementia
than the untreated group. In fact, the prevalence of the treated
group was equivalent to the general, age-comparable population.
The non-lithium-treated patients had an incidence of dementia
that was six times greater (5% on lithium vs. 33% no lithium;
Nunes et al., 2007). Although this study remains to be validated,
it suggests lithium as a potential therapeutic for AD.
A recent, more promising, lithium study differed from
previous ones in two ways: it was long-term (2 years) and
involved patients who had mild cognitive impairment (MCI),
not AD. The researchers measured the CSF biomarkers: Aβ42,
phosphorylated tau and total tau, and assessed cognitive
performance and drug safety. There was a significantly lower
concentration of phosphorylated tau in the CSF of lithium-
treated patients compared to those receiving a placebo, but there
were no differences in the levels of Aβ42 and total tau. The
lithium-treated group also had fewer conversions from mild
cognitive impairment to AD, but this number was statistically
insignificant. Nonetheless, the investigators believe their results
show that lithium may slow the disease progression from
cognitive impairment to dementia (Forlenza et al., 2011).
Huntington’s Disease
In the 1970s, there were several clinical trials of lithium therapy
for patients with HD. These trials included only small numbers
of patients (9, 6, and 6) for very short time periods (6–12
weeks). In each case, the findings indicated that there were no
improvements in involuntary movements, hyperkinesia, motor
skills, or in the ability to perform everyday tasks, leading to
the conclusion that lithium did not appear to be of therapeutic
value in HD (Aminoff and Marshall, 1974; Leonard et al., 1975;
Vestergaard et al., 1977). Since the 1970s, there have not been
any reported human clinical trials utilizing lithium for treatment
of HD; however, there has been a recent off-label use of lithium
in a case study involving three individuals. Each of the patients
received low doses of lithium and showed no further progression
of chorea over periods of 2–4 years (Danivas et al., 2013).
Other studies showed that lithium treatment suppresses
striatal lesions, reduces neurodegeneration, and stimulates cell
proliferation in an excitotoxic rat model of HD. It has also
been shown to reduce poly(Q) toxicity in cell models of
HD; significantly improve motor performance (albeit with no
improvement in longevity) in an HD mouse model; and protect
against poly(Q)-mediated toxicity in a Drosophila model of HD
(Wei et al., 2001; Carmichael et al., 2002; Wood and Morton,
2003; Senatorov et al., 2004; Berger et al., 2005). Two different
studies looked at the results of combining lithium with a second
mood-stabilizing drug to improve the efficacy of the treatment.
Sarkar et al. showed that the treatment of an HD fly model with
lithium in concert with rapamycin offered synergistic protection
against neurodegeneration compared with either agent alone
(Sarkar et al., 2008). Furthermore, there was better motor deficit
improvement in two different mouse models of HD co-treated
with lithium and valproate compared with monotherapy (Chiu
et al., 2011).
Amyotrophic Lateral Sclerosis
The protective effects of lithium in ALS were detailed in two
papers (Fornai et al., 2008a,b). These include the normalization
of the structure of altered mitochondria found in motor
neurons as well as the removal of intracellular aggregates from
motor neurons via increased autophagy; a stimulatory effect on
mitochondrial biogenesis; inhibition of astroglial growth and
proliferation; and neuronal differentiation. In a parallel study
using human ALS patients and the G93A mouse (an ALS
genetic animal model), researchers found that lithium provided
significant neuroprotection. In the human trial, which lasted 15
months, the progression of the disease was significantly reduced
in the lithium-treated group compared to the control group
treated with riluzole for the same time period, while the mutant
mice exhibited delayed onset of the disease and a longer life
span (Fornai et al., 2008b). In another study with G93A mice
in the same year, lithium in concert with valproic acid (VPA)
was reported to delay the onset of ALS symptoms, increase
life span, and the mice exhibited fewer neurological deficits as
compared to mice treated with lithium or VPA alone (Feng et al.,
2008). These results led the authors to suggest that lithium offers
some promise as a treatment for human patients affected by
ALS. In contrast, a subsequent multi-center consortium study
reported that lithium treatment was not universally effective in
ameliorating its symptoms in human patients (Chiò et al., 2010).
Based on the results from the Fornai et al. studies, a large 13-
month phase II screening trial of lithium carbonate in ALS was
undertaken in 2011. In contrast to earlier results, the researchers
concluded that lithium carbonate does not slow the rate of
decline of function in patients with ALS, as compared to a control
group, and the lithium-treated patients showed no differences in
quality of life and weremore prone to adverse events (Miller et al.,
2011). Around the same time, another randomized, double-blind,
placebo-controlled trial showed similar negative results, and in
fact, the trial was terminated prematurely because of futility
(Aggarwal et al., 2010). These trials have demonstrated some
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safety concerns and the lack of promising therapeutic benefits
from lithium treatment in ALS patients.
The inconsistent efficacy of lithium in treating ALS may
be due to the fact that ALS is a complex disease with a
constellation of cellular and molecular pathways involved in
its pathophysiology. There has been a small subset of patients
that demonstrated some improvement; however, it may be that
lithium does not selectively target the pathways that would
provide benefits to a majority of the cases. Another factor
to consider is that there may be an optimal dose of lithium,
which can be unique to each individual’s disease stage, required
to alleviate symptoms and prevent the pathology. However,
most clinical trials were likely performed without identifying
the optimal doses for patients. While some patients may show
improvement with a standard dose, that dose in others may
not impact on their pathophysiology or may create undesirable
side-effects.
CONCLUSIONS
Numerous in vitro and in vivo studies have shown that lithium
provides potential therapeutic value in the prevention and/or
treatment of neurodegenerative conditions. Multiple different
biological mechanisms have been shown to contribute to these
protective effects including the up-regulation of neuroprotective
proteins including Bcl-2 and its actions on regulation of
apoptosis and cellular resilience, such as GSK-3. Further clinical
and experimental studies with lithium are needed to determine
if the cellular and molecular biological properties of the drug
can be a part of a therapeutic strategy for Parkinson’s and other
neurodegenerative diseases. Lithium-only treatment may not
be a suitable therapeutic for neurodegenerative diseases due to
inconsistent efficacy and potential side-effects, however, the use
of low dose of lithium in combination with other potential or
existing therapeutic compoundsmay be a promising prophylactic
approach to reduce symptoms and disease progression in
neurodegenerative diseases.
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